Malu G Tansey

List of Publications by Year in Descending Order

89 papers	8,466 citations	46 h-index	92 g-index
93 ext. papers	9,777 ext. citations	8.1 avg, IF	6.4 L-index

#	Paper	IF	Citations
89	Is LRRK2 the missing link between inflammatory bowel disease and Parkinson's disease?. *Npj Parkinson's Disease*, **2021**, 7, 26	9.7	9
88	Gut microbiome differences between amyotrophic lateral sclerosis patients and spouse controls. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2021**, 1-9	3.6	8
87	Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation. *Movement Disorders*, **2021**, 36, 25-36	7	22
86	Adolescent stress sensitizes the adult neuroimmune transcriptome and leads to sex-specific microglial and behavioral phenotypes. *Neuropsychopharmacology*, **2021**, 46, 949-958	8.7	10
85	Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease. *Molecular Neurodegeneration*, **2021**, 16, 6	19	54
84	Peripheral and central immune system crosstalk in Alzheimer disease - a research prospectus. *Nature Reviews Neurology*, **2021**, 17, 689-701	15	18
83	Lysosome and Inflammatory Defects in GBA1-Mutant Astrocytes Are Normalized by LRRK2 Inhibition. *Movement Disorders*, **2020**, 35, 760-773	7	39
82	Molecular Signatures of Neuroinflammation Induced by Synuclein Aggregates in Microglial Cells. *Frontiers in Immunology*, **2020**, 11, 33	8.4	31
81	Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson's Disease. *Molecules*, **2020**, 25,	4.8	14
80	Characterization of a Cul9-Parkin double knockout mouse model for Parkinson's disease. *Scientific Reports*, **2020**, 10, 16886	4.9	0
79	Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson's disease: A case series. *Neurobiology of Disease*, **2020**, 144, 105027	7.5	16
78	The gut microbiome and neuroinflammation in amyotrophic lateral sclerosis? Emerging clinical evidence. *Neurobiology of Disease*, **2020**, 135, 104300	7.5	4
77	Spinal Motor Circuit Synaptic Plasticity after Peripheral Nerve Injury Depends on Microglia Activation and a CCR2 Mechanism. *Journal of Neuroscience*, **2019**, 39, 3412-3433	6.6	19
76	Chronic psychological stress during adolescence induces sex-dependent adulthood inflammation, increased adiposity, and abnormal behaviors that are ameliorated by selective inhibition of soluble tumor necrosis factor with XPro1595. *Brain, Behavior, and Immunity*, **2019**, 81, 305-316	16.6	9
75	LRRK2 regulation of immune-pathways and inflammatory disease. *Biochemical Society Transactions*, **2019**, 47, 1581-1595	5.1	49
74	Targeting soluble tumor necrosis factor as a potential intervention to lower risk for late-onset Alzheimer's disease associated with obesity, metabolic syndrome, and type 2 diabetes. *Alzheimer's Research and Therapy*, **2019**, 12, 1	9	39
73	Chronic adolescent stress sex-specifically alters central and peripheral neuro-immune reactivity in rats. *Brain, Behavior, and Immunity*, **2019**, 76, 248-257	16.6	25

72	Immune system responses in Parkinson's disease: Early and dynamic. *European Journal of Neuroscience*, **2019**, 49, 364-383	3.5	52
71	Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease. *Movement Disorders*, **2018**, 33, 793-804	7	77
70	An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2018**, 19, 242-249	3.6	19
69	Neuroinflammation in Age-Related Neurodegenerative Diseases **2018**, 477-507		
68	Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson's Disease Pathogenesis. *Frontiers in Neuroscience*, **2018**, 12, 626	5.1	17
67	Microglial phenotypes in Parkinson's disease and animal models of the disease. *Progress in Neurobiology*, **2017**, 155, 57-75	10.9	143
66	Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice. *Neurobiology of Disease*, **2017**, 102, 81-95	7.5	63
65	The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis?. *Npj Parkinson's Disease*, **2017**, 3, 3	9.7	252
64	LRRK2 **2017**, 107-116		1
63	Parkinsonism without dopamine neuron degeneration in aged l-dopa-responsive dystonia knockin mice. *Movement Disorders*, **2017**, 32, 1694-1700	7	6
62	Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease. *Journal of Neuroinflammation*, **2017**, 14, 164	10.1	34
61	A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation. *Journal of Neuroinflammation*, **2017**, 14, 128	10.1	34
60	Toll-like Receptor 4 Mediates Morphine-Induced Neuroinflammation and Tolerance via Soluble Tumor Necrosis Factor Signaling. *Neuropsychopharmacology*, **2017**, 42, 661-670	8.7	75
59	Chronic psychological stress and high-fat high-fructose diet disrupt metabolic and inflammatory gene networks in the brain, liver, and gut and promote behavioral deficits in mice. *Brain, Behavior, and Immunity*, **2017**, 59, 158-172	16.6	53
58	Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia. *JCI Insight*, **2017**, 2,	9.9	47
57	RGS10 deficiency ameliorates the severity of disease in experimental autoimmune encephalomyelitis. *Journal of Neuroinflammation*, **2016**, 13, 24	10.1	15
56	RGS10 Negatively Regulates Platelet Activation and Thrombogenesis. *PLoS ONE*, **2016**, 11, e0165984	3.7	20
55	Physiology of RGS10 in Neurons and Immune Cells. *Progress in Molecular Biology and Translational Science*, **2015**, 133, 153-67	4	14

54	The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins. *Human Molecular Genetics*, **2015**, 24, 4250-67	5.6	40
53	Age-related changes in regulator of G-protein signaling (RGS)-10 expression in peripheral and central immune cells may influence the risk for age-related degeneration. *Neurobiology of Aging*, **2015**, 36, 1982-93	5.6	14
52	Two weeks of predatory stress induces anxiety-like behavior with co-morbid depressive-like behavior in adult male mice. *Behavioural Brain Research*, **2014**, 275, 120-5	3.4	26
51	A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets. *Experimental Neurology*, **2014**, 256, 126-32	5.7	41
50	Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro® 1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats. *Journal of Parkinson's Disease*, **2014**, 4, 349-60	5.3	50
49	AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease. *PLoS ONE*, **2014**, 9, e96544	3.7	6
48	Selective effects of a therapeutic protein targeting tumor necrosis factor-alpha on cytochrome P450 regulation during infectious colitis: Implications for disease-dependent drug-drug interactions. *Pharmacology Research and Perspectives*, **2014**, 2, e00027	3.1	8
47	Role of the Innate and Adaptive Immune System in the Pathogenesis of PD **2014**, 75-103		1
46	Analysis of inflammation-related nigral degeneration and locomotor function in DJ-1(-/-) mice. *Journal of Neuroinflammation*, **2013**, 10, 50	10.1	17
45	Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity. *ASN Neuro*, **2013**, 5, 113-39	5.3	166
44	Progranulin does not bind tumor necrosis factor (TNF) receptors and is not a direct regulator of TNF-dependent signaling or bioactivity in immune or neuronal cells. *Journal of Neuroscience*, **2013**, 33, 9202-13	6.6	71
43	Tumor necrosis factor-neuropeptide Y cross talk regulates inflammation, epithelial barrier functions, and colonic motility. *Inflammatory Bowel Diseases*, **2013**, 19, 2535-46	4.5	39
42	The role of innate and adaptive immunity in Parkinson's disease. *Journal of Parkinson's Disease*, **2013**, 3, 493-514	5.3	181
41	Critical role of regulator G-protein signaling 10 (RGS10) in modulating macrophage M1/M2 activation. *PLoS ONE*, **2013**, 8, e81785	3.7	30
40	Microglia isolation from adult mouse brain. *Methods in Molecular Biology*, **2013**, 1041, 17-23	1.4	77
39	Isolation of murine postnatal brain microglia for phenotypic characterization using magnetic cell separation technology. *Methods in Molecular Biology*, **2013**, 1041, 33-9	1.4	18
38	Regulation of microglia effector functions by tumor necrosis factor signaling. *Glia*, **2012**, 60, 189-202	9	42
37	Quantitative analysis of the detergent-insoluble brain proteome in frontotemporal lobar degeneration using SILAC internal standards. *Journal of Proteome Research*, **2012**, 11, 2721-38	5.6	51

36	RNF11 modulates microglia activation through NF-B signalling cascade. *Neuroscience Letters*, **2012**, 528, 174-9	3.3	25
35	RGS10 exerts a neuroprotective role through the PKA/c-AMP response-element (CREB) pathway in dopaminergic neuron-like cells. *Journal of Neurochemistry*, **2012**, 122, 333-43	6	24
34	Ceramide sphingolipid signaling mediates Tumor Necrosis Factor (TNF)-dependent toxicity via caspase signaling in dopaminergic neurons. *Molecular Neurodegeneration*, **2012**, 7, 45	19	38
33	Psychological stress in adolescent and adult mice increases neuroinflammation and attenuates the response to LPS challenge. *Journal of Neuroinflammation*, **2012**, 9, 9	10.1	64
32	Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson's disease?. *Current Neurology and Neuroscience Reports*, **2012**, 12, 350-8	6.6	54
31	The duality of TNF signaling outcomes in the brain: potential mechanisms?. *Experimental Neurology*, **2011**, 229, 198-200	5.7	13
30	The Role of Neuroinflammation in Parkinson's Disease **2011**, 403-421		4
29	Lipopolysaccharide and tumor necrosis factor regulate Parkin expression via nuclear factor-kappa B. *PLoS ONE*, **2011**, 6, e23660	3.7	82
28	Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. *Molecular Therapy*, **2011**, 19, 46-52	11.7	86
27	Regulator of G-protein signaling-10 negatively regulates NF-B in microglia and neuroprotects dopaminergic neurons in hemiparkinsonian rats. *Journal of Neuroscience*, **2011**, 31, 11879-88	6.6	57
26	TNF: a key neuroinflammatory mediator of neurotoxicity and neurodegeneration in models of Parkinson's disease. *Advances in Experimental Medicine and Biology*, **2011**, 691, 539-40	3.6	54
25	Modeling neuroinflammatory pathogenesis of Parkinson's disease. *Progress in Brain Research*, **2010**, 184, 113-32	2.9	67
24	Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. *Neurobiology of Disease*, **2010**, 37, 510-8	7.5	726
23	Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. *Neurobiology of Disease*, **2009**, 34, 163-77	7.5	204
22	Neuroinflammation in Parkinson's disease. *Journal of NeuroImmune Pharmacology*, **2009**, 4, 419-29	6.9	119
21	Does neuroinflammation fan the flame in neurodegenerative diseases?. *Molecular Neurodegeneration*, **2009**, 4, 47	19	505
20	The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection. *Journal of Neuroinflammation*, **2008**, 5, 14	10.1	68
19	TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. *Journal of Neuroinflammation*, **2008**, 5, 45	10.1	574

18	Autologous transplants of Adipose-Derived Adult Stromal (ADAS) cells afford dopaminergic neuroprotection in a model of Parkinson's disease. *Experimental Neurology*, **2008**, 210, 14-29	5.7	67
17	Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. *Molecular Therapy*, **2008**, 16, 1572-9	11.7	95
16	Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. *Journal of Neuroscience*, **2008**, 28, 10825-34	6.6	206
15	Regulator of G-protein signaling 10 promotes dopaminergic neuron survival via regulation of the microglial inflammatory response. *Journal of Neuroscience*, **2008**, 28, 8517-28	6.6	74
14	Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's disease. *Journal of Inflammation Research*, **2008**, 1, 29-39	4.8	32
13	Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy?. *Frontiers in Bioscience - Landmark*, **2008**, 13, 709-17	2.8	83
12	Cytokines in CNS Inflammation and Disease **2008**, 59-106		15
11	Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. *Experimental Neurology*, **2007**, 208, 1-25	5.7	397
10	Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. *Journal of Neuroscience*, **2006**, 26, 9365-75	6.6	289
9	Gamma-secretase activity is dispensable for mesenchyme-to-epithelium transition but required for podocyte and proximal tubule formation in developing mouse kidney. *Development (Cambridge)*, **2003**, 130, 5031-42	6.6	161
8	Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. *Science*, **2003**, 301, 1895-8	33.3	188
7	c-Src is required for glial cell line-derived neurotrophic factor (GDNF) family ligand-mediated neuronal survival via a phosphatidylinositol-3 kinase (PI-3K)-dependent pathway. *Journal of Neuroscience*, **2001**, 21, 1464-72	6.6	127
6	GFRalpha-mediated localization of RET to lipid rafts is required for effective downstream signaling, differentiation, and neuronal survival. *Neuron*, **2000**, 25, 611-23	13.9	248
5	Functional mapping of receptor specificity domains of glial cell line-derived neurotrophic factor (GDNF) family ligands and production of GFRalpha1 RET-specific agonists. *Journal of Biological Chemistry*, **2000**, 275, 3412-20	5.4	49
4	Persephin, a novel neurotrophic factor related to GDNF and neurturin. *Neuron*, **1998**, 20, 245-53	13.9	421
3	Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. *Neuron*, **1998**, 21, 1291-302	13.9	487
2	Inhibition of phosphatidylinositol 3-kinase activity blocks depolarization- and insulin-like growth factor I-mediated survival of cerebellar granule cells. *Journal of Biological Chemistry*, **1997**, 272, 9847-53	5.4	215
1	TrnR2, a novel receptor that mediates neurturin and GDNF signaling through Ret. *Neuron*, **1997**, 18, 793-802	13.9	309